What we do Jubilant Pharmova Limited is a global pharmaceutical and life sciences company specializing in pharmaceuticals, life science ingredients, and drug discovery solutions. |
Founded in 1,978 |
Market share Leading player with strong presence in Radiopharma, CDMO, allergy immunotherapy, CRDMO and generics sectors. |
Problem solved Provides high-quality pharmaceuticals, specialty products, and innovative drug discovery to address unmet clinical needs globally. |
Top clients or who we serve Serves global pharmaceutical companies, hospitals, radiopharmacies, allergists, and biotech firms; B2B and B2C markets. |
Key management Involves experienced leadership including Managing Director Priyavrat Bhartia and Joint Managing Director Arjun S Bhartia. |
Our journey and innovations Evolved from chemicals to pharmaceuticals with major acquisitions, R&D centers, and innovation in radiopharma and novel drug discovery. |
Where we operate Operates across India, USA, Canada, Europe, and other international markets serving 50+ countries. |
Top products or what we offer Radiopharmaceuticals, sterile injectables, allergy immunotherapy products, generics, APIs, and drug discovery services. |
Top brands Ruby-Fill (market leading cardiac PET), HollisterStier (allergy therapy), Jubilant Pharma (generics and APIs). |
Raw materials needed Includes chemical intermediates for pharmaceuticals, radioisotopes for radiopharma, and specialty chemicals. |
Raw materials supplier Various global chemical and isotope suppliers aligned with regulatory standards. |
Recurring vs cyclical contribution Revenue mainly recurring from pharmaceuticals and CDMO; proprietary novel drugs still in investment phase. |
Our industry position Strong market position in North American radiopharma and CDMO markets with diversified pharma segments. |
Financial highlights Consolidated revenue approximately ₹72,345 million in FY25 with 26.9% EBITDA growth and ₹8,363 million net profit. |
Geographical revenue split 80% revenue from Americas and Europe, 10% from India, rest from other global markets. |
Order book Robust order book from established pharma clients and long-term supply contracts in radiopharma and CDMO. |
Whats driving growth Growth from radiopharmaceutical innovation, expansion in CDMO capacity, strategic partnerships, and novel drug trials. |
Our future plans Expand injectable capacity in Spokane, develop new PET/SPECT products, and scale up proprietary drug pipeline. |
Our green promise Commits to sustainability with reduced emissions, water conservation, and zero liquid discharge across plants. |
Our people and values Global workforce of ~5,500 fostering an inclusive, agile, and safety-first culture emphasizing employee development. |
Key challenges ahead Regulatory compliance, market pricing pressures, supply chain risks, and scaling novel drugs commercialisation. |
Interesting facts Operates the second largest radiopharmacy network in the US with 45 pharmacies serving 1,800+ hospitals. |
Risks and strategy Manages risks with robust quality systems, diversified portfolio, strategic investments, and active compliance management. |
